Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison

Psychiatry Research

Volumn 189, Issue 3, 2011, Pages 349-356

  Cianchetti, Carlo ^a   Ledda, Maria Giuseppina ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Clozapine; Haloperidol; Olanzapine; Psychotic disorders; Risperidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAINTENANCE DRUG DOSE; MALE; MOOD CHANGE; MOOD DISORDER; NEUTROPHIL; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053445177     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.03.020     Document Type: Article

References (27)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, APA, Washington, DC. Fourth Edition.
2. Armenteros J.L., Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. European Child & Adolescent Psychiatry 2006, 15:141-148.
3. Castro-Fornieles J., Parellada M., Soutullo C.A., Baeza I., Gonzalez-Pinto A., Graell M., Paya B., Moreno D., de la Serna E., Arango C. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. Journal of Child and Adolescent Psychopharmacology 2008, 18:327-336.
4. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association 2009, 302:1765-1773.
5. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976, 33:766-771.
6. Findling R.L., Johnson J.L., McClellan J., Frazier J.A., Vitiello B., Hamer R.M., Lieberman J.A., Ritz L., McNamara N.K., Lingler J., Hlastala S., Pierson L., Puglia M., Maloney A.E., Kaufman E.M., Noyes N., Sikich L. Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49:583-594.
7. Fleischhaker C., Heiser P., Hennighausen K., Herpertz-Dahlmann B., Holtkamp K., Mehler-Wex C., Rauh R., Remschmidt H., Schulz E., Warnke A. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. Journal of Child and Adolescent Psychopharmacology 2006, 16:308-316.
8. Fraguas D., Correll C.U., Merchan-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled studies. European Neuropsychopharmacology 2011, 21:621-645.
9. Gallhofer B., Bauer U., Lis S., Krieger S., Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European Neuropsychopharmacology 1996, 6(Suppl 2):S13-S20.
10. ECDEU Assessment Manual for Psychopharmacology 1976, Department of Health, Education, and Welfare, Rockville, MD, U.S. W. Guy (Ed.).
11. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
12. Kumra S., Frazier J.A., Jacobsen L.K., McKenna K., Gordon C.T., Lenane M.C., Hamburger S.D., Smith A.K., Albus K.E., Alaghband-Rad J., Rapoport J.L. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Archives of General Psychiatry 1996, 53:1090-1097.
13. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., De Thomas C., Kafantaris V., Correll C.U., Kane J.M. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry 2008, 63:524-529.
14. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., De Thomas C., Cullen K., Regan J., Kane J.M. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. Journal of Child and Adolescent Psychopharmacology 2008, 18:307-316.
15. Ledda M.G., Fratta A.L., Pintor M., Zuddas A., Cianchetti C. Early-onset psychoses: comparison of clinical features and adult outcome in 3 diagnostic groups. Child Psychiatry and Human Development 2009, 40:421-437.
16. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
17. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
18. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry 2006, 163:600-610. CATIE Invetigators.
19. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999, 25:233-255.
20. Rodriguez V.M., Catalina M.L., Garcìa-Noblejas J.A., Cuesta P. Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia. Psychiatry Research 1998, 77:21-28.
21. Shaffer D., Gould M.S., Brasic J., Ambrosini P., Fisher P., Bird H., Aluwahlia S. A children's global assessment scale (CGAS). Archives of General Psychiatry 1983, 40:1228-1231.
22. Shaw P., Sporn A., Gogtay N., Overman G.P., Greenstein D., Gochman P., Tossell J.W., Lenane M., Rapoport J.L. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry 2006, 63:721-730.
23. Sikich L., Hamer R.M., Bashford R.A., Sheitman B.B., Lieberman J.A. A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004, 29:133-145.
24. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., Ambler D., Puglia M., Maloney A.E., Michael E., De Jong S., Slifka K., Noyes N., Hlastala S., Pierson L., McNamara N.K., Delporto-Bedoya D., Anderson R., Hamer R.M., Lieberman J.A. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American Journal of Psychiatry 2008, 165:1420-1431.
25. Sporn A.L., Vermani A., Greenstein D.K., Bobb A.J., Spencer E.P., Clasen L.S., Tossell J.W., Stayer C.C., Gochman P.A., Lenane M.C., Rapoport J.L., Gogtay N. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:1349-1356.
26. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanene A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
27. Wehmeier P.M., Schüler-Springorum M., Heiser P., Remschmidt H. Chart review for potential features of myocarditis, pericarditis and cardiomyopathy in children and adolescents treated with clozapine. Journal of Child and Adolescent Psychopharmacology 2004, 4:267-271.